Why Is Ionis Pharmaceuticals (IONS) Down 16.4% Since Last Earnings Report?Zacks Investment Research • 12/09/22
Ionis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALSPRNewsWire • 12/05/22
Ionis partners with Metagenomi to add gene editing to its broad technology platformPRNewsWire • 11/14/22
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual MeetingPRNewsWire • 11/13/22
Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsenPRNewsWire • 11/08/22
Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022PRNewsWire • 11/07/22
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?Investors Business Daily • 10/20/22
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug TestInvestors Business Daily • 09/23/22
Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemiaPRNewsWire • 09/23/22
Why Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?Zacks Investment Research • 09/08/22
Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on AmyloidosisPRNewsWire • 09/07/22